Your browser doesn't support javascript.
Nirmatrelvir-ritonavir treatment of COVID-19 in a high-risk patient population: A retrospective observational study.
Kane, Anna M; Keenan, Erica M; Lee, Kasheng; Hartkopf, Katherine J; Ludwig, Trisha A; Trapskin, Philip J; Vanderloo, Joshua P; Schulz, Lucas T.
  • Kane AM; Department of Pharmacy UW Health Madison Wisconsin USA.
  • Keenan EM; Department of Pharmacy UW Health Madison Wisconsin USA.
  • Lee K; Department of Pharmacy UW Health Madison Wisconsin USA.
  • Hartkopf KJ; Department of Pharmacy UW Health Madison Wisconsin USA.
  • Ludwig TA; Department of Pharmacy UW Health Madison Wisconsin USA.
  • Trapskin PJ; Department of Pharmacy UW Health Madison Wisconsin USA.
  • Vanderloo JP; Department of Pharmacy UW Health Madison Wisconsin USA.
  • Schulz LT; Department of Pharmacy UW Health Madison Wisconsin USA.
J Am Coll Clin Pharm ; 6(1): 29-33, 2023 Jan.
Article in English | MEDLINE | ID: covidwho-2157827
ABSTRACT

Background:

Coronavirus disease 2019 (COVID-19) is a highly contagious, airborne viral infection that can infect anyone. Those with certain underlying conditions may be at higher risk for infection to develop into a severe disease requiring hospitalization. This report summarizes use of nirmatrelvir-ritonavir for the treatment of COVID-19 in high-risk patients at a single academic medical center through a pharmacist delegation protocol and demonstrates real-world efficacy and safety of treatment.

Methods:

This retrospective, single-center, observational study analyzed all patients who received nirmatrelvir-ritonavir ordered by a clinical pharmacist for treatment of COVID-19 infection. The primary outcomes were safety and efficacy of nirmatrelvir-ritonavir. Safety was evaluated by analyzing drug interaction management and adverse events. Efficacy was evaluated through hospitalization and death within 28 days of nirmatrelvir-ritonavir use.

Results:

Sixty patients were eligible for inclusion. No patients were hospitalized or died within 28 days after initiation of nirmatrelvir-ritonavir. Pharmacists identified 101 drug interactions with 60% considered clinically significant, requiring modification of home medications. Adverse outcomes associated with the use of nirmatrelvir-ritonavir were reported in 13 patients (21.7%).

Conclusions:

A comprehensive program to mitigate drug interactions and prescribe nirmatrelvir-ritonavir ensured timely access to COVID-19 therapy, which may be associated with the prevention of hospitalization and death.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study Language: English Journal: J Am Coll Clin Pharm Year: 2023 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study Language: English Journal: J Am Coll Clin Pharm Year: 2023 Document Type: Article